93 results
8-K
NBSE
NeuBase Therapeutics Inc
3 May 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:00pm
, on November 3, 2023, NeuBase Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock
8-K
NBSE
NeuBase Therapeutics Inc
5 Apr 24
NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
4:16pm
Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq
8-K
EX-99.1
NBSE
NeuBase Therapeutics Inc
5 Apr 24
NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
4:16pm
) (“NeuBase” or the “Company”) today reported that it received a notice (the “Notice) on April 4, 2024 from the Listing Qualifications Department
8-K
EX-10.1
j607epjhg525e3 sz05
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
8-K
EX-10.2
py7 3p2j6
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
424B5
fh1kf34pax9
30 Jun 23
Prospectus supplement for primary offering
8:42am
424B5
se2y9eu
29 Dec 22
Prospectus supplement for primary offering
5:03pm
8-K
EX-10.1
yxew6sizssie7yposyh
29 Dec 22
Entry into a Material Definitive Agreement
4:06pm
8-K
EX-10.1
nmh4d
1 Oct 21
Departure of Directors or Certain Officers
4:17pm
424B5
bk4otu2lq33r
27 Aug 21
Prospectus supplement for primary offering
5:21pm
8-K
EX-1.1
vs65g5i6p3zes sm
27 Aug 21
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.2
erd 1mg7ftggx
8 Jun 21
Regulation FD Disclosure
2:01pm
8-K
EX-10.1
gckb qpp5dtndz
25 May 21
NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer
9:00am